Publications

Recent Publications

1. Staller DW, Panigrahi SS, Jayasinghe YP, Dong Y, Mahto S, Kumar V, Ronning DR, Mahato RI. A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases. Hepatology. 2024 Jul 1:10-97.
2. Shrestha P, Ghanwatkar Y, Mahto S, Pramanik N, Mahato RI. Gemcitabine–Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice. ACS Applied Materials & Interfaces. 2024 May 30.
3. Kumar V, Sethi B, Staller DW, Shrestha P, Mahato RI. Gemcitabine elaidate and ONC201 combination therapy for inhibiting pancreatic cancer in a KRAS mutated syngeneic mouse model. Cell Death Discovery. 2024 Mar 29;10(1):158.
4. Kumar V, Sethi B, Staller DW, Xin X, Ma J, Dong Y, Talmon GA, Mahato RI. Anti-miR-96 and Hh pathway inhibitor MDB5 synergistically ameliorate alcohol-associated liver injury in mice. Biomaterials. 2023 Apr;295:122049. doi: 10.1016/j.biomaterials.2023.122049. Epub 2023 Feb 17. PMID: 36827892; PMCID: PMC9998370.
5. Sethi B, Kumar V, Jayasinghe TD, Dong Y, Ronning DR, Zhong HA, Coulter DW, Mahato RI. Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma. J Control Release. 2023 Feb;354:80-90. doi: 10.1016/j.jconrel.2022.12.055. Epub 2023 Jan 5. PMID: 36599397; PMCID: PMC9974792.
6. Ma J, Kumar V, Mahato RI. Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease. Pharmaceutics. 2022 Sep 7;14(9):1894. doi: 10.3390/pharmaceutics14091894. PMID: 36145643; PMCID: PMC9501368.
7. Bhattarai RS, Bariwal J, Kumar V, Hao C, Deng S, Li W, Mahato RI. pH-sensitive nanomedicine of novel tubulin polymerization inhibitor for lung metastatic melanoma. J Control Release. 2022 Oct;350:569-583. doi: 10.1016/j.jconrel.2022.08.023. Epub 2022 Sep 2. PMID: 36037976; PMCID: PMC10322201.
8. Kumar V, Sethi B, Yanez E, Leung DH, Ghanwatkar YY, Cheong J, Tso J, Narang AS, Nagapudi K, Mahato RI. Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate. Int J Pharm. 2022 Mar 5;615:121470. doi: 10.1016/j.ijpharm.2022.121470. Epub 2022 Jan 15. PMID: 35041913.
9. Kumar, V., Wang, Q., Sethi, B., Lin, F., Kumar, V., Coulter, D. W., ... & Mahato, R. I. (2021). Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma. Biomaterials, 278, 121138. https://doi.org/10.1016/j.biomaterials.2021.121138
10. Bhattarai, R. S., Kumar, V., Romanova, S., Bariwal, J., Chen, H., Deng, S., ... & Mahato, R. I. (2021). Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. Journal of Controlled Release, 329, 585-597.https://doi.org/10.1016/j.jconrel.2020.09.052